Clinical trials: Neoplasms by Site, open to volunteers
Endometrial Neoplasms, DNA Methylation
Cervical Cytology DNA Methylation for Endometrial Lesion Screening and Follow-up
The goal of this observational study is to evaluate the accuracy of a novel molecular test for screening and monitoring endometrial lesions in women at medium-to-high risk for endometrial cancer.
- Conditions
- Endometrial Neoplasms, DNA Methylation, Cervical Smears, Early Detection of Cancer
- Trial name
- EndoMethy-V (NCT07298707)
- Volunteers
- 3,500 people
- Sponsor
- Peking Union Medical College Hospital
Head and Neck Squamous Cell Carcinoma
Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell Carcinoma
A multicenter, randomized, controlled, open-label, Phase II/III clinical trial designed to evaluate the efficacy and safety of postoperative radiotherapy combined with Nimotuzumab,with or without Bemcentinib, in postoperative…
- Trial name
- NimoBenSeq (NCT07535567)
- Testing
- Nimotuzumab, Nimotuzumab, Benmelstobart, Postoperative Radiotherapy
- Volunteers
- 386 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Thyroid Papillary Carcinoma, Contrast Enhanced Ultrasound
Preoperative Prediction of Lymph Node Metastasis in T1N0M0 Papillary Thyroid Carcinoma by Using Contrast-enhanced Ultrasound
Similarly, the burden of central lymph node metastasis affects the individualized management of patients with T1N0M0 papillary thyroid carcinoma (PTC): lymph node metastasis is a contraindication to thermal ablation; low-burden…
- Trial name
- NCT07357571
- Where
- 2 sites in China
- Volunteers
- 600 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NSCLC (Non-small Cell Lung Cancer), Neoadjuvant Immunotherapy
A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC
The goal of this clinical trial is to learn if tislelizumab in combination with anlotinib and platinum-based doublet chemotherapy works to treat for resectable stage II-IIIB driver gene-negative NSCLC.
- Conditions
- NSCLC (Non-small Cell Lung Cancer), Neoadjuvant Immunotherapy, Adjuvant Immunotherapy
- Trial name
- NCT06977828
- Testing
- tislelizumab in combination with anlotinib and platinum-based doublet chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Endometrial Cancer
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer.
- Trial name
- NCT06481592
- Testing
- Lifileucel
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Ovarian Cancer
ChemoINTEL Assay Algorithm Development Study: In-Vitro Cytotoxic Drug Induced Apoptosis Correlation with Patient Clinical Response to Administered Chemotherapy in Patients
This is a prospective, non-randomized, observational, clinical development study. Pierian Biosciences is utilizing ChemoINTEL and ImmunoINTEL assay measurements in human tumour cells from patients with advanced stage epithelial…
- Trial name
- ChemoINtel (NCT06844136)
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Pierian Biosciences
Stomach Neoplasms, Gastric Cancer
Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer
The aim of this study is to test the efficacy and safety of immunotherapy plus chemotherapy on people with a relatively rare type of gastric cancer.
- Conditions
- Stomach Neoplasms, Gastric Cancer, Linitis Plastica of Stomach
- Trial name
- Neo-ICEBOAT (NCT06451211)
- Testing
- Tislelizumab, Oxaliplatin, S-1
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Sun Yat-sen University
Oral Leukoplakia
Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia
This is a Phase IIa oral cavity leukoplakia study of pioglitazone 15mg and metformin 500mg BID for 12 weeks. The primary objective is to determine the clinical and histologic changes of leukoplakia from baseline following a 12…
- Trial name
- NCT05727761
- Testing
- pioglitazone-metformin
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- University of Minnesota
Prostate Cancer
ABlative Radiotherapy (for) Unfavorable Prostate Tumors
Published clinical evidence confirms that a single dose of 24 Gy provides unprecedented long-term local control in primary and metastatic prostate cancer with safe toxicity profiles, provided that exposure of surrounding healthy…
- Trial name
- ABRUPT (NCT04831983)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Milano Bicocca
Nasopharyngeal Carcinoma (NPC), Screening
"Xijiang Project" Screening Cohort for NPC
The purpose of this study is to establish a comprehensive and integrated nasopharyngeal carcinoma screening cohort, which includes an epidemiological information database containing basic information, gender, age, ethnic and…
- Trial name
- NCT06787456
- Testing
- EBV antibodies test, EBV DNA test, epidemiological information survey
- Where
- China
- Volunteers
- 1,000,000 people, healthy volunteers welcome
- Sponsor
- Ming-Yuan Chen
Nasopharyngeal Carcinoma, Radiotherapy
Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma
Through multicenter, open-label, randomised clinical trials, we intend to demonstrate that radiotherapy with reduced dose could significantly reduce the incidence of radiotherapy toxicities, improve the quality of life of…
- Conditions
- Nasopharyngeal Carcinoma, Radiotherapy, Chemotherapy
- Trial name
- NCT04448522
- Testing
- reduced dosage IMRT, conventional dosage IMRT
- Where
- 6 sites in China, Singapore
- Volunteers
- 508 people
- Sponsor
- Sun Yat-sen University
Breast Cancer
Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
This trial is to investigate if in patients with clinically node positive breast cancer undergoing upfront surgery, treatment with TAS and ART is superior to ALND in terms of arm-related Quality of Life (QoL) and occurrence of…
- Trial name
- OPBC-10/ NOAX (NCT07140172)
- Testing
- Axillary lymph node dissection (ALND), Axillary radiotherapy (ART)
- Where
- 55 sites in United States, Austria and 9 more
- Volunteers
- 1,060 people
- Sponsor
- University Hospital, Basel, Switzerland
Posterior Fossa Lesion
Comparison of Surgical Outcomes of Craniotomy and Craniectomy in Posterior Fossa Lesions
The purpose of this randomized controlled trial is to compare the surgical outcomes of craniotomy and craniectomy among patients with posterior fossa lesions.
- Trial name
- NCT06831695
- Testing
- Craniotomy, Craniectomy
- Volunteers
- 80 people
- Sponsor
- University of Health Sciences Lahore
Breast Cancer
Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer
The objective of this non-interventional study (NIS) is to evaluate prevalence of ESR1 mutation after endocrine therapy in the palliative setting, quality of life, tolerability, and safety and to describe treatment detail and…
- Trial name
- ELENI (NCT07563595)
- Testing
- Elacestrant, Standard of care (Investigator Choice)
- Where
- 3 sites in Germany
- Volunteers
- 500 people
- Sponsor
- iOMEDICO AG
Head and Neck Cancer, Radiation-Induced Mucositis
A Randomized Controlled Study on the Improvement of Medical Experience for Patients With Radiation-induced Oropharyngeal Mucositis Based on the RIS System of the Internet of Things
This study is a researcher-initiated, multi-center, prospective, two-arm interventional randomized controlled study across the country.
- Trial name
- NCT07126457
- Testing
- RIS system
- Where
- 4 sites in China
- Volunteers
- 110 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Gastric Cancer, Gastroesophageal Junction Cancer
GRACE-DE: Prospective Multicenter Real-world Gastric Cancer Patients Starting AZ-developed and Approved Drugs in Germany (Umbrella Study)
This is a prospective, non-interventional, observational, multicentre study evaluating the real-world effectiveness and safety of AstraZeneca-developed and approved medicines used to treat gastric and/or oesophageal cancers in…
- Trial name
- GRACE-DE (NCT07882212)
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
Colorectal Cancer
Impact of a Proactive Strategy of General Practitioners on CRC Screening
In this registry-based cluster randomized controlled trial, we will assess the impact of a proactive strategy of general practitioners (GP) who will systematically provide screening kits of colorectal cancer (CRC) to all patients…
- Trial name
- DECORE (NCT06664567)
- Testing
- Colorectal cancer screening test
- Volunteers
- 26,260 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Small Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage Small Cell Lung Cancer
This study aims to investigate the clinical value of small extracellular vesicle (sEV) miRNAs as predictive biomarkers for immunochemotherapy efficacy in extensive-stage small cell lung cancer (ES-SCLC).
- Trial name
- NCT07070011
- Testing
- EC/EP + ICIs
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Shanghai Chest Hospital of Shanghai Jiao Tong University
Ovarian Cancer
Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovarian Cancer Who Are Refractory to Platinum-based Therapy From Patients Defined as Long-term Responders to Platinum-based Therapy
After having constituted the ORTRAI cohort using the CONSORE database at the Jean PERRIN Center, the objective is to characterize the patients both clinically and biologically, histologically and genomically.
- Trial name
- ORTRAI (NCT07361471)
- Testing
- molecular analysis
- Where
- France
- Volunteers
- 55 people
- Sponsor
- Centre Jean Perrin
Non-Small Cell Lung Cancer
A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer
To evaluate the safety and efficacy of SYS6010 combined with osimertinib as neoadjuvant therapy for patients with resectable EGFR mutation non-squamous non-small cell lung cancer.
- Trial name
- NCT07256509
- Testing
- SYS6010, Osimertinib, Pemetrexed
- Volunteers
- 120 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.